December 19, 2018 by Chain Drug Review
Emma Walmsley, GlaxoSmithKline, Pfizer, Tobias Hestler
Business, Featured Articles, Leading Headlines, News, Pharmacy

NEW YORK — GlaxoSmithKline Plc and Pfizer Inc. have struck a deal that will create the largest over-the-counter drug company in the world. GSK paved the way for a split into two companies, agreeing to create the consumer-health joint venture with Pfizer. GSK, according to the deal, with retain a 68% controlling stake in the new
August 8, 2018 by Chain Drug Review
Emma Walmsley, GlaxoSmithKline, Iain Mackay, Philip Hampton, Simon Dingemans
Leading Headlines, Supplier News

LONDON — GlaxoSmithKline (GSK) announced that Iain Mackay has been appointed GSK’s next chief financial officer (CFO). He has also been appointed as an Executive Director to the GSK board. Mackay will join the company on January 14, 2019. Mackay joins GSK from the global bank HSBC, where he has been Group Finance Director for
March 27, 2018 by Chain Drug Review
consumer health care, Emma Walmsley, GlaxoSmithKline, GSK-Novartis Consumer Healthcare, Novartis, Pfizer Consumer Healthcare, Vas Narasimhan
Business, Leading Headlines, Pharmacy, Supplier News

LONDON and BASEL, Switzerland — GlaxoSmithKline plc plans to buy Novartis’ 36.5% stake in their consumer health care joint venture for $13 billion. Under the agreement announced Tuesday, Novartis’ shares in the joint venture will be canceled, and the joint venture will pay the buyout price to Novartis. GSK has entered into a committed facilities agreement to
September 30, 2016 by Chain Drug Review
Andrew Witty, Brian McNamara, Emma Walmsley, GlaxoSmithKline, GSK Consumer Healthcare
Business, Leading Headlines, Pharmacy, Supplier News

LONDON — Brian McNamara has been promoted to chief executive officer of GlaxoSmithKline plc’s consumer health business. GSK said McNamara assumes the GSK Consumer Healthcare CEO post and joins GSK’s corporate executive team effective immediately. He takes the reins from Emma Walmsley, who just over a week ago was named to succeed Sir Andrew Witty
September 20, 2016 by Chain Drug Review
Andrew Witty, Emma Walmsley, GlaxoSmithKline, GSK Consumer Healthcare, Philip Hampton, video
Business, Leading Headlines, Pharmacy, Supplier News, Videos

LONDON — Emma Walmsley has been named to succeed Sir Andrew Witty as chief executive officer of GlaxoSmithKline plc. The drug maker said Tuesday that Walmsley, CEO of GSK Consumer Healthcare, is slated to take the reins from Witty when he retires on March 31, 2017. Plans call for her to become a member of